Germany rethinking drug price reforms after Lilly, Boehringer withdraw investments: Reuters

Weeks after Boehringer Ingelheim and Eli Lilly retracted billions of dollar in German commitments, the nation’s government is reportedly changing a contentious element of its planned healthcare reforms.